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ARTICLE
The long non-coding RNA LUCAT1 is a negative
feedback regulator of interferon responses
in humans
Shiuli Agarwal1, Tim Vierbuchen 1, Sreya Ghosh1, Jennie Chan1, Zhaozhao Jiang1, Richard K. Kandasamy2,
Emiliano Ricci 3 & Katherine A. Fitzgerald 1✉
Long non-coding RNAs are important regulators of biological processes including immune
responses. The immunoregulatory functions of lncRNAs have been revealed primarily in
murine models with limited understanding of lncRNAs in human immune responses. Here, we
identify lncRNA LUCAT1 which is upregulated in human myeloid cells stimulated with lipo-
polysaccharide and other innate immune stimuli. Targeted deletion of LUCAT1 in myeloid
cells increases expression of type I interferon stimulated genes in response to LPS. By
contrast, increased LUCAT1 expression results in a reduction of the inducible ISG response. In
activated cells, LUCAT1 is enriched in the nucleus where it associates with chromatin. Fur-
ther, LUCAT1 limits transcription of interferon stimulated genes by interacting with STAT1 in
the nucleus. Together, our study highlights the role of the lncRNA LUCAT1 as a post-
induction feedback regulator which functions to restrain the immune response in human cells.
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Type-I Interferon (IFN-α/β) production and signaling isinstrumental for effective anti-viral immunity. The type IIFN response is initiated upon recognition of pathogen-
associated molecular patterns (PAMPs) such as viral nucleic acids
or lipopolysaccharide (LPS). The main transcription factors that
induce the production of IFN-α/β are the interferon regulatory
factor 3 (IRF3) and IRF7. Interferons themselves are potent
cytokines that induce the expression of hundreds of interferon-
stimulated genes (ISGs) in an auto- and paracrine manner
through binding to the heterodimeric interferon receptor
(IFNAR). ISGs interfere with viral replication and support
pathogen clearance1. The activation of IFN-α/β signaling is tightly
regulated through the JAK-STAT1 signaling pathway and dys-
regulation of this signaling pathway can lead to persistent
inflammation and autoimmune diseases such as lupus2–4.
While the importance of numerous protein players in these
pathways has been well elucidated, the role of non-coding RNAs
(ncRNAs) in the regulation of the IFN response is less well
understood. Amongst the various classes of ncRNAs, micro RNAs
(miRNAs) and long non-coding RNAs (lncRNAs) are the most
widely studied in biological processes including host–pathogen
interactions5,6.
With over 17,000 lncRNAs encoded by the human genome,
this group constitutes the largest class of ncRNAs and represents
a large portion of human genes (Gencode v327,8). Arbitrarily
described as greater than 200 bp in length and lacking protein-
coding capacity, lncRNAs have been shown to modulate tran-
scription, translation, and post-transcriptional processing of
mRNAs in a species- and tissue-specific manner9,10. lncRNAs can
either act in cis to alter the expression of neighboring genes or act
in trans and execute various functions throughout the cell. These
ncRNAs can exhibit diverse roles in cellular and developmental
processes but also in diseases such as cancer11–13, auto-
immunity14, and cardiovascular disease15,16. A limited number of
lncRNAs have been discovered and characterized as immune
regulators including lncRNA-COX217, THRIL18, lncRNA-EPS19,
and Morrbid20,21. The molecular mechanisms that underlie the
immunoregulatory functions for these RNAs are diverse. For
example, lncRNA-COX2 and THRIL are nuclear lncRNAs that
form complexes with heterogenous nuclear ribonucleoproteins
(hnRNPs) to alter the expression of target genes17,19, whereas
Neat1 translocates to the cytoplasm to promote inflammasome
assembly and stabilize Caspase-1, an inflammatory caspase that
controls the proteolytic maturation of interleukin-1 beta (IL-1β)
and related cytokines22. LncRNAs are poorly conserved between
humans and mice, with most of the studies that have been con-
ducted to date being in murine models.
LUCAT1 was first identified as Smoke and Cancer Associated
lncRNA-1 (SCAL1) in lung cancer cells23. LUCAT1/SCAL1 is
induced upon exposure of human lung cell lines to cigarette
smoke in a KEAP1-NRF2 dependent manner and shown to
protect cells from oxidative stress23. Since this initial discovery,
LUCAT1 has been associated with various forms of cancer and
plays a pivotal role in tumorigenesis by promoting cell migra-
tion24, cell proliferation25, and metastasis24,26–28. Furthermore,
LUCAT1 was shown to be highly upregulated in retinal muller
glial cells upon Toxoplasma gondii infection indicating a potential
role in host–pathogen interactions29. However, very little is
known about how LUCAT1 influences immune responses in
human cells.
In this study, we utilize high-throughput RNA sequencing on
LPS-stimulated or virus infected human dendritic cells (DCs) and
identify LUCAT1 as one of the strongest induced lncRNAs.
lncRNA LUCAT1 is a dynamically regulated gene that functions
as a potent regulator of the IFN-α/β response. Genetic ablation of
LUCAT1 using virus-like particles loaded with Cas9 and sgRNA,
so-called Nanoblades, results in hyperactivation of ISGs and
proinflammatory cytokines in the human monocytic cell line
THP-1 as well as in primary human DCs following LPS stimu-
lation. Accordingly, overexpression of LUCAT1 in THP-1 cells
using CRISPR activation (CRISPRa) attenuates the inducible
IFN-α/β response. We show that LUCAT1 interacts with STAT1
in the nucleus and in doing so restrains ISG expression. The
induction of LUCAT1 is therefore a post-induction feedback
regulatory mechanism to limit the magnitude and duration of the
IFN-α/β response.
Results
LUCAT1 is an inducible lncRNA in activated primary human
cells. To assess lncRNA expression, we performed RNA
sequencing in primary human monocyte-derived dendritic cells
(hMDDC) stimulated with LPS, herpes simplex virus 1 (HSV-1),
and influenza A virus (IAV) for 2 and 6 h. RNA sequencing data
from these cells revealed differential expression of several non-
coding transcripts many of which were induced in a ligand-
specific manner (Fig. 1a). Among these lncRNAs was a previously
described lncRNA, LUCAT123, which showed significant increase
in expression after stimulation with all three ligands (Supple-
mentary Fig 1a). LUCAT1 reaches the maximum induction as
early as 2 h post LPS stimulation (Fig. 1b). We also employed RT-
qPCR to validate these findings, which showed rapid and sig-
nificant LPS-induced expression of LUCAT1 at 2 h in primary
human CD14+monocytes, DCs, and macrophages (Fig. 1c). RT-
qPCR analysis of LUCAT1 expression also showed significant
induction with IAV and HSV-1 in a time-dependent manner in
hMDDC (Supplementary Fig 1b). Additionally, the human
monocytic cell lines THP-1 as well as BLaER1 cells, which can be
transdifferentiated into a monocyte-like phenotype30, also dis-
played significant enrichment of LUCAT1 in a time-dependent
manner when stimulated with LPS (Supplementary Fig 1c, d).
RT-qPCR measures levels of RNA transcripts in cells which could
result from RNA transcription or alterations in the stability of
RNAs31. We wanted to understand the kinetics of LUCAT1
expression further and employed metabolic pulse-chase labeling
of RNA using 4-thiouridine (4sU) in LPS-stimulated hMDDCs,
followed by qPCR using exon-spanning primers. By comparing
labeled RNA to total RNA, we validated the kinetics of LUCAT1
induction. We observed that the mature LUCAT1 RNA was
newly transcribed maximally by 2 h, consistent with the RT-
qPCR analysis. The kinetics of IFN-β mRNA overlapped that of
LUCAT1 (Fig. 1d). As expected, we did not observe changes in
the expression of the housekeeping gene GAPDH (Fig. 1d).
Absolute quantification of LUCAT1 RNA revealed that LUCAT1
is expressed at low copy numbers in resting cells but upregulated
to ~ 50 copies per cell upon LPS stimulation (Fig. 1e).
In contrast to protein-coding genes, lncRNAs are expressed at
lower abundance and have poorly annotated transcription start
and end sites7. To identify the 5′ and 3′ sequence ends of
LUCAT1 transcripts, we performed Rapid Amplification of
cDNA Ends (RACE) from LPS-stimulated hMDDCs. Through
sequencing of the RACE products, we could identify isoforms
with the predicted 5′ ends from the two LUCAT1 isoforms
(NR_103548.1 and NR_103549.1) in the RefSeq database
(Supplementary Fig 1e). Although none of the sequenced RACE
clones yielded the 3′ ends from the two RefSeq isoforms, we were
able to identify a 3′ end that had been predicted by several
isoforms in the Ensembl database (e.g., ENST00000648773.1).
There are currently 61 different LUCAT1 isoforms annotated in
Ensembl (release 99). We cloned LUCAT1 transcripts using
primers specific to the 5′ and 3′ ends that have been determined
by RACE as well as a 3′ primer for the longer isoform
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NR_103548.1. Sequencing of these clones confirmed their
expression in hMDDCs. Figure 1f depicts the 14 distinct
LUCAT1 isoforms we detected (Fig. 1f) which highlights the
diversity of LUCAT1 isoforms found in human DCs.
Engagement of TLR4 following LPS stimulation leads to
activation of MyD88-dependent and TRIF-dependent signaling
pathways that culminate in the activation of NF-κB and IRF3,
critical transcription factors that control expression of immune
response genes and type I IFNs. To evaluate the contribution of
NF- κB and the IFN-α/β pathway in the inducible expression of
lncRNA LUCAT1, we used Bay11-7082, an irreversible inhibitor
of the IKK kinases at the concentrations 0.1 µM and 0.3 µM, and
Tofacitinib, a JAK1/JAK3 inhibitor (which would block signaling
from the receptor for type I IFNs amongst other pathways) at the
concentrations 0.1, 0.3, and 1 µM. hMDDCs were preincubated
with these inhibitors at the indicated concentrations for 30 min
and then treated with LPS for 2 h. RT-qPCR analysis showed that
the inducible expression of LUCAT1 was significantly impaired
using either NF-κB or JAK inhibition in a dose-dependent
manner (Fig. 1g, h). The levels of IL-6, an NF-κB regulated gene
b

































































































































































































































Fig. 1 LUCAT1 is an inducible lncRNA upregulated in activated primary human cells upon immune stimulation. a Venn diagram showing number of
differentially upregulated lncRNAs in LPS, HSV-1, and IAV treated hDCs (log 2 TPM> 2). b Heatmap of lncRNAs differentially expressed non-coding RNA
(log 2 TPM > 2 fold over NT, Q value < 2) following LPS, HSV-1, IAV treatment at 2 h and 6 h in hDCs. c RT-qPCR analysis of LUCAT1 expression in human
DCs(Left) (n= 4 donors); one-way ANOVA Dunnett’s multiple comparisons test), CD14+monocytes (middle) (n= 3 donors; unpaired t-test) and human
macrophages (Right) upon LPS stimulation (n= 2 donors; one-way ANOVA Dunnett’s multiple comparisons test). d Pulse chase 4SU incorporation in
LUCAT1, IFNβ, and GAPDH mRNA in LPS-stimulated hDCs. e RT-qPCR analysis for absolute copy number of LUCAT1 in LPS-stimulated hDCs (n= 3
donors; one-way ANOVA Dunnett’s multiple comparisons test). f Schematic showing identified and predicted isoforms of LUCAT1 in LPS-stimulated hDCs.
g hDCs were pretreated with NF-κB inhibitor Bay 11 followed by LPS stimulation. RT-qPCR analysis showing LUCAT1 expression in hDCs. (n= 3, one-way
ANOVA Dunnett’s multiple comparisons test). h hDCs were pretreated with JAK1 inhibitor Tofacitinib followed by LPS stimulation. RT-qPCR analysis
showing LUCAT1 expression in hDCs (n= 3, one-way ANOVA Dunnett’s multiple comparisons test). Data is represented as mean ± SEM, **P≤ 0.01,
****P≤ 0.0001.
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were dose dependently blocked by Bay11-7082, while the levels of
the ISG RSAD2 were blocked by JAK inhibition as positive
controls in these assays (Supplementary Fig 1e, f). Collectively,
these results indicate that LUCAT1 is induced by multiple TLR
ligands and viral infection in human monocytic cells.
LUCAT1 deficiency results in a hyper-inflammatory gene sig-
nature. We next wanted to evaluate the possibility that LUCAT1
was a regulator of the inducible inflammatory response. Given,
the challenges in generating primary human transgenic cells, we
have made use of a CRISPR/Cas9-based approach, so-called
Nanoblades32, to target LUCAT1 in primary human cells.
Nanoblades are engineered murine leukemia VLPs loaded with
Cas9/sgRNA ribonucleoproteins32. By transfecting HEK-293T
cells with plasmids encoding Gag:Cas9, Gag-Pro-Pol, a single-
guide RNA (sgRNA), and viral envelopes, fusogenic VLPs are
produced and released in the culture medium. Human DCs were
incubated with Nanoblades loaded with two sgRNAs per com-
bination and three different groups of Nanoblades were used for
targeting the genomic locus and excision of LUCAT1 (Supple-
mentary Fig 2a). Using RT-qPCR analysis of targeted polyclonal
cells we found that there was effective deletion of LUCAT1 in
LPS-stimulated hMDDC in all three Nanoblade sgRNA combi-
nations (Fig. 2a). To assess the impact of LUCAT1 deletion on the
transcriptome, we used RNA sequencing to evaluate basal and
LPS-inducible gene expression in LUCAT1 sufficient and defi-
cient hMDDCs. RNA-seq analysis showed tight correlation
between two technical replicates in all NTC control and LUCAT1
Nanoblades N1, N2, N3 at both resting state and LPS-treated
hMDDC (Supplementary Fig 2b). Gene Ontology (GO) enrich-
ment analysis showed enrichment of inflammatory response
genes all of which were elevated in cells lacking LUCAT1
(Fig. 2b). The most differentially regulated genes included IFN-β
as well as the IFN-stimulated genes ISG15, IFITM3, IFIT3, IFIT1,
IFI44, and CCL5 in all three Nanoblade combinations (Fig. 2c, d).
This observation was consistent with the findings that LUCAT1
depletion only lead to hyperactivation of a subset of inflammatory
genes, as several immune and non-immune genes were unchan-
ged between the two groups (Supplementary Fig 2d). We also
validated these findings in hMDDC using RT-qPCR by measur-
ing IFN-β (Fig. 2e) and using Nanostring to measure the
expression of a panel of 50 inflammatory and IFN-stimulated
genes (Supplementary Fig 2c). The Nanostring analysis showed
elevated levels of IFN-β, ISGs, and inflammatory response genes
in all three Nanoblade sgRNA combinations following LPS sti-
mulation relative to NTC cells treated with LPS (Supplementary
Fig 2c).
We also confirmed these findings using a different cell system.
We used Nanoblades to target LUCAT1 in THP-1 cells which
resulted in efficient deletion of LUCAT1 (Fig. 3a). RT-qPCR
analysis of these cells showed an elevated IFN-β and CXCL10
response following LPS stimulation in LUCAT1-depleted cells
when compared to NTCs (Fig. 3b, c). A similar increase was
observed after Sendai Virus (SeV) infection of LUCAT1-/-
THP1 cells (Supplementary Fig. 3a, b). The elevated expression
of IFN-β and CXCL10 mRNA was also seen at the protein level in
these LUCAT1 knock out THP-1 cells as compared to control
cells upon LPS stimulation (Fig. 3d). We also generated short
hairpin RNA (shRNA)-expressing THP-1 cells targeting LUCAT1
RNA. THP-1 expressing shRNA showed more than 50 percent
knock down of LUCAT1 (Fig. 3e). Consistent with our findings
using CRISPR-based Nanoblades, we observed a large increase in
expression of IFN-β and IL-6 in these cells while the inducible
levels of TNF-α were comparable between cell lines (Fig. 3f–h). A
heatmap showing the most differentially regulated genes
measured using Nanostring is shown in (Fig. 3i). Similar studies
were performed using LUCAT1 shRNA-expressing BLaER1 cells.
Optimal knock down of LUCAT1 resulted in elevated IFN-β
expression in BLaER1 upon LPS and Sendai virus (SeV) challenge
(Supplementary Fig 3d, e).
Next, we performed gain-of-function studies to overexpress
LUCAT1 from its endogenous locus. THP-1 cells expressing
catalytically inactive Cas9 (dCas9) fused to the transcriptional
activator VP64 were transduced with sgRNA containing viral
supernatant and selected for puromycin resistance. CRISPRa-
mediated overexpression is enabled by recruitment of transcrip-
tion coactivators to target gene loci33. Five LUCAT1 targeting
sgRNA were designed within −200 bp of the transcription start
site (TSS). These gRNAs led to at least a 3-fold enhancement of
LUCAT1 expression in THP1 cells (Fig. 3j). When these cells
were then challenged with LPS and SeV we observed a significant
decrease in inducible IFN-β gene expression compared to the
control sgRNA expressing cell lines (Fig. 3k, l). These results
indicate that expression of LUCAT1 reduced the inducible
expression of these genes.
LUCAT1 is enriched in the nucleus and associates with chro-
matin. Defining the cellular distribution of lncRNAs is crucial to
understand their biological function34. A large proportion of
lncRNAs are retained in the nucleus where they regulate chro-
matin structure and accessibility as well as transcription of target
genes34,35. In order to define the localization of LUCAT1, we
prepared nuclear and cytoplasmic fractions of LPS-stimulated
THP-1 cells and measured LUCAT1 levels in these fractions by
RT-qPCR. We observed enrichment of LUCAT1 in the nuclear
compartment in LPS-treated cells (Fig. 4a). To validate and
expand on these findings we next performed single-molecule
RNA fluorescence in situ hybridization (smFISH) on hMDDCs
which confirmed these findings. While there were low levels of
LUCAT1 in cells in the absence of stimulation, the levels of
LUCAT1 increased and were enriched in the nucleus upon sti-
mulation in primary hMDDC (Fig. 4b, Supplementary Fig 4a).
We observed a speckled staining pattern of LUCAT1 in the
nucleus, which was significantly higher in cells treated with LPS
than in resting cells (Fig. 4c). We next performed RNA immu-
noprecipitation (RIP) using Histone H3 antibody to determine if
LUCAT1 was enriched in the chromatin fraction of cells. Indeed,
histone H3 RIP followed by RT-qPCR analysis showed enrich-
ment of lncRNA LUCAT1 following LPS stimulation. This was
similar to what we found for MALAT1, a known chromatin-
bound lncRNA36 (Fig. 4d). Together, these findings clearly
indicate the presence of LUCAT1 in multiple locations within the
nucleus and its association with chromatin.
LUCAT1 transcriptionally regulates cytokines by associating
with STAT1. We next wanted to understand if LUCAT1 was
acting to alter transcription of IFN-β and ISGs. We performed
Chromatin Immunoprecipitation (ChIP) followed by qPCR to
assess the recruitment of RNA polymerase II (RNA pol II) and
H3K4 trimethylation, a marker of active transcription at target
gene loci. The recruitment of RNA pol II to the promoters of the
IFN-β and RSAD2 genes was significantly enhanced in cells sti-
mulated with LPS (Fig. 5a, b). When LUCAT1 levels were
reduced by shRNA, there was increased RNA pol II binding at the
promoters of both IFN-β and RSAD2 genes compared to control
cells indicating that the increased expression of IFN-β and ISGs
was likely due to increased transcription of these target genes.
Similarly, there was an increase in H3K4me3 observed at the
promoter of IFN-β and RSAD2 in LUCAT1-deficient cells in both
untreated and LPS-stimulated conditions (Fig. 5c, d).
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These observations suggest that LUCAT1 normally restrains
the transcription of IFN-β and ISGs. To better understand how
LUCAT1 might mediate this effect we wanted to identify protein
binding partners of LUCAT1 in the chromatin fraction of cells.
We performed comprehensive identification of RNA-binding
proteins by mass spectrometry (ChIRP-MS) in primary
hMDDCs37. LPS-treated primary cells were chemically cross-
linked and sonicated to achieve optimal RNA fragments. Cell
lysates were then incubated with biotinylated ssDNA probes that
were antisense to LUCAT1 and enriched using streptavidin beads.
Proteins associated with these complexes were then identified by
MS. Proteomics analysis of LPS-treated samples identified many
nuclear proteins in LUCAT1 pull downs (Supplementary Data 1).
Amongst these were histones as well as STAT1. To further
confirm these findings, we performed RIP using STAT1 antibody.
STAT1 complexes were pulled down from nuclear extracts of
LPS-stimulated cells and the levels of LUCAT1 measured by RT-
qPCR (Fig. 5e). In contrast to STAT1 pulldowns, antibody to
IRF3 or IgG had no LUCAT1 binding. Since these studies
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Fig. 2 LUCAT1 deficiency leads to hyperactivation of an inflammatory and ISG signature. Nanoblades were used to generate LUCAT1-deficient hDCs
using three combinations of sgRNA; Nano1 (N1), Nano2 (N2), and Nano3 (N3). a RT-QPCR analysis for LUCAT1 gene expression in hDCs upon LPS
stimulation in control, N1, N2, and N3 (n= 3, biologically independent experiments with 3 different donors, one-way ANOVA Dunnett’s multiple
comparisons test). b Gene Ontology analysis showing enrichment of immune pathways in Nanoblade-mediated LUCAT1 depleted hDCs in LPS-stimulated
conditions. Unbiased RNA sequencing was performed in Nano1, Nano2, Nano3, and NTC hDCs. c Scatterplot analysis showing differentially regulated
genes in FPKM values LUCAT1 Nanoblade hDCs compared to NTC controls in LPS-stimulated conditions. d Bar graph representation of top
proinflammatory genes (in FPKM) differentially regulated between Nanoblade-targeted LUCAT1 hDCs and NTC controls in LPS-stimulated conditions.
e RT-QPCR analysis of IFNβ expression in Nanoblade-mediated LUCAT1 targeting in hDC cells upon LPS stimulation (n= 3, biologically independent
experiments with 3 different donors, Nano1 (N1), Nano2 (N2), and Nano3 (N3, one-way ANOVA Dunnett’s multiple comparisons test). Data in a, e is
represented as mean ± SEM. Data in d is represented as mean ± SD, **P≤ 0.01.
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if STAT1 function was altered in cells lacking LUCAT1. To this
end, we evaluated STAT1 binding to the promoters of ISGs using
STAT1 ChIP-qPCR in WT and LUCAT1-deficient THP1 cells
stimulated with LPS (Fig. 5f–i). We observed increased occupancy
of STAT1 at the promoter regions of IFI16 and MX2 in cells
lacking LUCAT1. All together these results indicate that LUCAT1
associates with STAT1 in the nucleus and alters STAT1 function
by reducing STAT1 binding at ISGs to modulate their
transcription.
Discussion
Type I interferons are a family of cytokines which function pri-
marily to elicit immune responses against viruses and bacteria in
an autocrine, paracrine, and systemic manner. In addition, acti-
vation of type I IFNs can also lead to cellular proliferation, dif-
ferentiation, and migration, all of which impact type I IFN-
mediated pathogen clearance and restoration of tissue home-
ostasis. Although, activation of type I IFN is important for pro-
tective immunity during infection, excessive production of type I
IFN leads to chronic inflammation and tissue damage as char-
acterized by many autoimmune disorders including systemic
lupus erythematosus (SLE), Sjogren’s syndrome, and
Aicardi–Goutières syndrome (AGS)38,39. Therefore, tight reg-
ulation of type I IFN responses is necessary to maintain immune
homeostasis. The type I IFN response is mediated by binding of
IFNα/β to the heterodimeric IFNα/β receptor (IFNAR1/IFNAR2)
which results in phosphorylation of receptor-associated tyrosine
kinases, tyrosine kinase 2 (TYK2), and Janus kinase 1 (JAK1).
Phosphorylation of TYK2 and JAK1 in turn activate signal
transducer and activators of transcription 1 (STAT1) and STAT2
by phosphorylating tyrosine residues. Phosphorylated
STAT1–STAT2 heterodimers translocate to the nucleus and form
an IFN-stimulated gene factor 3 complex (ISGF3) complex with
IRF92,3,40. Binding of the ISGF3 complex to the promoters of
IFN-stimulated genes (ISGs) is important for induction of these
genes and effective anti-microbial responses2–4.
JAK1-STAT signaling also leads to upregulation of various
immunomodulatory proteins which act in a negative feedback
a cb
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Fig. 3 LUCAT1 deficiency leads to hyperactivation of an inflammatory and ISG signature. Nanoblades were used to generate LUCAT1-deficient THP-1
using two combinations of sgRNA; Nano1 (N1) and Nano2 (N2). a–c RT-QPCR analysis for LUCAT1 (a), IFNβ (b) and CXCL10 (c) gene expression in THP-1
upon LPS stimulation (n= 2; biologically independent experiments, unpaired t-test) d Culture supernatant was analyzed by ELISA for CXCL10 levels in LPS-
stimulated LUCAT1 KO THP-1 cells at 6 h time point. (n= 3; biologically independent experiments; unpaired two-tailed t-test, p= 0.0015) e–h RT-QPCR
analysis of LUCAT1 (e), IFNβ (f), IL6 (g), and TNF (h) gene expression in LUCAT1 shRNA expressing THP-1 cells upon LPS stimulation (n= 3; biologically
independent experiments; unpaired two tailed t-test, p= 0.0001; p= 0.0011; p= 0.0148 respectively). i Heat map representing top differentially regulated
genes using Nanostring analysis for a code set of human proinflammatory genes in LUCAT1 shRNA expressing THP-1 cells (n= 2; biologically independent
experiments). LUCAT1 was overexpressed from its endogenous loci using VP64 THP-1 cells. Five sgRNA were designed from −200 bp to TSS to
overexpress LUCAT1. j RT-qPCR analysis of LUCAT1 gene expression in resting THP-1 VP64 LUCAT1 overexpressing cells (n= 2, biologically independent
generated overexpressing cells over 2 experiments). j–l RT-qPCR analysis showing j LUCAT1 overexpession in THP-1 VP64 cells; k IFNΒ expression upon
LPS stimulation, or l SeV infection in THP-1 VP64 LUCAT1 overexpressing cells. (n= 2, biologically independent generated overexpressing cells over 2
experiments). Data is represented as mean ± SEM *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P≤ 0.0001.
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manner to turn off the IFN-α/β signaling. Negative regulation of
the type I IFN pathway involves numerous protein factors that act
to limit PRRs, PRR signaling, and as well as IFN signaling itself.
Suppressor of cytokine signaling (SOCS1 and SOCS3) proteins,
specifically SOCS1 is a potent negative regulator of type I IFN
signaling and functions by reducing TYK2 and STAT1 phos-
phorylation. SOCS1 deficiency has been associated with increased
ISG transcription, cytokine production, and enhanced pathogen
clearance in murine models41,42. Similarly, Src homology phos-
phatase proteins (SHP1 and SHP2) inhibit phosphorylation of
signaling molecules including STAT1 and JAK1 to downregulate
type I IFN signaling43. Many negative regulators of type I IFN
signaling bind to the receptor itself to alter signaling. USP18 is an
example of one such protein that binds IFNAR1/IFNAR2 and
displaces JAK1, thus altering its binding preference to low-affinity
IFN-α, thereby decreasing the overall strength of type I IFN
signaling44,45. In addition to these protein regulators of the type I
IFN response, a growing body of literature has identified non-
coding RNAs including miRNAs and lncRNAs, that are co-
expressed with ISGs. ncRNAs are known to have diverse roles in
regulation of immune pathways including inhibiting type I IFN
signaling by targeting STAT1 and STAT2 (miRNA 221/222),
suppression of IFNβ production (miRNA miR26a, miR34a,
miR145, and Let7b)46, and negative regulation of PRRs such as
RIG-I (miRNA-146a)47. Additionally, lncRNAs such as lncRNA-
CMPK2 have been shown to downregulate IFN-α/β responses by
acting in a negative feedback manner; however not many
lncRNAs are known that modulate IFN-α/β responses in human
cells48.
Here, we have identified LUCAT1 as a new regulator that
limits the type I IFN response in human myeloid cells. High-
throughput RNA sequencing revealed LUCAT1 as one the most
dynamically regulated lncRNAs in HSV-1, IAV-, and LPS-
stimulated hMDDCs as well as in other primary myeloid cells and
cell lines. The role of LUCAT1 in regulation of type I IFN
responses was further characterized by loss-of-function studies.
Unbiased transcriptome analysis on LUCAT1-depleted primary
hMDDCs showed an increased inflammatory gene signature that
predominantly included numerous STAT1-regulated genes such
as CCL5, IP10, IFIT1 and RSAD2. We also observe differential
regulation of other inflammatory genes such as NF-kB-driven IL-
6 and IL-10, suggesting a broader role of LUCAT1 in restraining
immune responses. Additionally, we utilized CRISPRa to generate
LUCAT1-overexpressing human monocytic cells. In contrast to
loss-of-function studies, increased levels of LUCAT1 suppressed
the expression of inflammatory genes and ISGs. A similar
observation was made in a diabetic model of a human lung cell
line, where overexpression of LUCAT1 led to decreased levels of
iNOS and NO49. These results provide compelling evidence that
LUCAT1 regulates an anti-inflammatory program specifically by
restraining the type I IFN and inflammatory response during
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Fig. 4 LncRNA LUCAT1 is enriched in nuclear compartment upon activation, and is associated with chromatin. a RT-qPCR analysis of GAPDH, LUCAT1,
and MALAT1 gene expression in nuclear and cytoplasmic fractions in LPS-stimulated THP-1 cells (n= 3, biologically independent experiments). b smFISH
analysis for LUCAT1 in primary human hDCs in stimulated conditions. LUCAT1 probes are represented in red, chromatin staining by DAPI in blue, and
GAPDH mRNA in green (n= 3, biologically independent experiments) c Quantification of LUCAT1 puncta in smFISH imaging in b (n= 3, biologically
independent experiments unpaired two-tailed t-test, p= 0.0099). d RT-qPCR analysis of LUCAT1 and MALAT1 gene expression in RNA
immunoprecipitation (RIP) samples using antibody against Histone H3 (n= 4 for LUCAT1 RIP and n= 2 for MALAT1 RIP, biologically independent
experiments; unpaired two-tailed t-test, LUCAT1 p= 0.0002; MALAT1 p= 0.0056). Data is represented as mean ± SEM *P≤ 0.05, **P≤ 0.01, ***P≤
0.001, ****P≤ 0.0001.
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Since lncRNAs impact biological process through a diversity of
mechanisms, it is informative to understand where in the cell
these RNAs are localized. Cellular localization dictates regulation
and function34,50. Numerous studies have shown that nuclear
localized lncRNAs modulate chromatin state, transcription, or
RNA splicing, contrary to lncRNAs in the cytosol, that can
interact with miRNAs, influence translation, or interact with host
proteins to alter post-translational modifications51. Both cellular
fractionation and smFISH in primary hMDDC revealed that
LUCAT1 is highly enriched in the nucleus following stimulation.
Nuclear-retained lncRNAs frequently associate with chromatin or
with protein factors in the nucleus. RIP of LUCAT1 revealed
enrichment of LUCAT1 with the histone subunit H3 confirming
its association with chromatin. The data supported by RNA pol II
and Histone H3K4 ChIP in LUCAT1-deficient cells also suggests
that LUCAT1 impacts transcription of its target genes.
With the advancement in techniques to interrogate
RNA–protein interactions more precisely, ChIRP-MS identified
protein binding partners of LUCAT1 from crosslinked cells. This
approach revealed a large number of LUCAT1 interacting pro-
teins in these pull downs. Amongst these proteins, histones and
STAT1 were identified. We confirmed this interaction by pulling
down STAT1 from nuclear extracts and examining associated
RNAs by qPCR. These two approaches indicated that LUCAT1
associates with STAT1. STAT1 is a master regulator of the type-I
IFN response. Its phosphorylation in response to IFNα/β leads to
its interaction with STAT2 and IRF9 to form the ISGF3 complex
which binds Interferon-stimulated response elements (ISRE) in
the promoters of ISGs to facilitate their transcription. Given that
LUCAT1-deficient cells express higher levels of ISGs, we hypo-
thesized that LUCAT1 interaction with STAT1 alters STAT1
function. There are at least two possibilities by which STAT1
function could be modulated. Firstly, LUCAT1 could sequester
STAT1 in the nucleus preventing STAT1 binding to the
promoters of ISGs. This would limit the ability of nuclear STAT1
to turn on ISG expression. Alternatively, LUCAT1 could associate
with STAT1 on the promoters of ISGs and recruit chromatin
modifying complexes or transcriptional repressors to alter chro-
matin state or block transcription of STAT1 target genes. ChIP
analysis revealed increased STAT1 binding to the promoters of
ISGs when LUCAT1 levels were limiting consistent with the
sequestration model outlined above. A better understanding of
these mechanisms could further enhance understanding of
lncRNA LUCAT1-mediated regulatory pathway for ISG
regulation.
Methods
Ethics. De-identified human blood products were obtained from the Rhode Island
Blood Center. Studies with human PBMC were conducted with approval from the
Institutional Review Board of the University of Massachusetts Medical School. All
donors provided written informed consent. All studies were approved by the
Instituitonal Biosafety committee at University of Massachusetts Medical School.
Human samples. Leukoreduction system (LRS) chambers from healthy donors
were obtained from the Rhode Island Blood Center. Peripheral blood mononuclear
cells (PBMCs) were obtained from LRS chambers by Lymphoprep density gradient
centrifugation (Stemcell Technologies, Cat#07851). CD14 positive monocytes were
isolated from PBMCs by magnetic cell separation (MACS) using CD14 microbeads
(Miltenyi, Cat#130-050-201). Purity of isolated CD14 positive cells was determined
using flow cytometry. Written informed consent was obtained from all leukocyte
donors.
Cell culture. THP-1 cell line was obtained from ATCC (Cat#ATCC TIB-202) and
maintained in RPMI 1640 (Corning, Cat#10-040-CV) supplemented with 10% FCS
and 1% Pen/Strep and were differentiated into macrophages in the presence of
10 ng/ml phorbol-12-myristate acetate (PMA, Sigma, Cat#P8139) for 12–16 h
followed by media change and resting for up to 48 h. CD14+monocytes were
differentiated into monocyte-derived Dendritic Cells (hMDDCs) using a cocktail of
hIL-4 and hGM-CSF (produced in 293T cells) in RPMI with 10% heat-inactivated,
pooled human AB serum (Sigma) for 7–8 days. CD14+monocytes were also




















































































































































































Fig. 5 Transcriptional regulation of IFN-I and ISGs by LUCAT1 and identification of STAT1 as a binding partner of lncRNA LUCAT1. a, b ChIP qPCR
analysis of Pol II at IFNβ (a) and RSAD2 (b) promoter in THP-1 cells expressing LUCAT1 shRNA in LPS-stimulated conditions (n= 2; biologically
independent experiments). c, d ChIP qPCR analysis of H3K4me3 at IFNβ (c) and RSAD2 (d) promoter in THP-1 cells expressing LUCAT1 shRNA in LPS-
stimulated conditions (n= 2, biologically independent experiments; unpaired t-test). e RNA Immunoprecipitation (RIP) was performed on human DCs
using STAT1 and IRF3 antibodies. RT-QPCR analysis for LUCAT1 and MALAT1 expression in hDCs (n= 3 biologically independent experiments with 3
different donors) f–i ChIP qPCR analysis of STAT1 at the binding sites of CXCL10 (p= 0.0705) (f), RSAD2 (p= 0.232) (g), IFI16 (p= 0.0488) (h), and
MX2 (p= 0.0496) (i) in LUCAT1-/- THP-1 cells and control cells. Cells were either untreated (NT) or stimulated with LPS for 4 h (n= 3; biologically
independent experiments, two-tailed paired t-test). Data is represented as mean ± SEM *P≤ 0.05.
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(Peprotech, Human Recombinant M-CSF, #300-25) in RPMI with 10% pooled
human AB serum (Sigma) for 5–6 days.
BLaER1 were obtained from Dr. Veit Hornung laboratory, Munich30,52 and
cultured in RPMI, 10% FCS, 1% Glutamine, 1% Pyruvate + 1% Pen/strep. For
differentiation, 105 cells in culture media was used in 96 well plate supplemented
with 10 ng/ml of hrIL-3 (PeproTech, Cat#200-03), 10 ng/ml hr-CSF-1 (M-CSF)
(PeproTech, Cat#300-25), and 100 nM β-Estradiol (Sigma-Aldrich, Cat#E8875)
and incubated for 5–6 days. Before stimulation, differentiation media was changed
to culture media.
CXCL10 ELISA. THP-1 wild type cells and THP-1 LUCAT1 KO cells were sti-
mulated with LPS at 2 ng/ml and 200 ng/ml for 6 h. Supernatants were collected
and diluted 1:5 in PBS+ 1% BSA buffer. Cytokine levels in supernatants were
measured by CXCL10 ELISA (R&D Systems, Cat#DY266) according to the man-
ufacturer’s instructions.
Reagents. Reagents used in the study were obtained from following sources: E. coli
LPS was purchased from Sigma-Aldrich (Cat#L2630); recombinant human M-CSF
(Peprotech, #300-25), NF-κB inhibitor BAY-7082 (Tocris Bioscience, Cat#1744),
Tofacitinib (Sigma, Cat#PZ0017), and HSV-1 (David Knipe Laboratory) Sendai
virus (Cantrell strain) were purchased from Charles River Laboratories (Wil-
mington, MA), GeneJuice was from Millipore, #70967-6. Customized nCounter
gene expression code-set was obtained from NanoString technologies
(Seattle, WA).
RNA sequencing and bioinformatics. Primary human DCs were treated with HSV-1
at MOI 10, IAV at MOI .5 and LPS (200 ng/ml) for 2 h and 6 h. Cells were washed
with cold PBS once and scraped. Pelleted cells were lysed in lysis buffer followed by
RNA extraction according to manufacturer’s protocol (Biorad Aurum Total RNA
mini Kit, #7326820). Strand-specific total RNA, with depletion of rRNA libraries
were generated with 1 µg of input RNA using the TruSeq Stranded Total RNA
Sample Prep Kit (Illumina, Cat#20020596) and sequenced on an Illumina HiSeq
machine. Paired-end sequence reads were aligned to the masked human genome
using Bowtie53 and expression analysis was performed with RSEM54 and EBSeq55.
The RSEM-calculate expression program was run with paired-end forward-probe
options and GTF version 84 from Ensembl. The EBSeqHMMTest function was
used to calculate posterior probabilities for potential expression patterns in the
time course experiment. The false discovery rate of genes was controlled at 5%,
which corresponds to a posterior probability of 0.95 or greater. A pseudo value of
one was added to TPM values prior to log transformations and calculation of fold-
change values. The data was deposited into GEO SuperSeries GSE145451.
RNA sequencing on LUCAT1 nanoblade clones in primary human DC samples. 1 µg
of total RNA from LUCAT1 Nanoblade clone and control cell stimulated with LPS
was sent to BGI for high-throughput RNA sequencing. The sequence reads were
aligned to human reference genome build hg19 using TopHat256 and Bowtie253.
FPKM (fragments per kilobase million) values were computed using Cufflinks and
fold changes were calculated using Cuffdiff57. Gene Ontology enrichment was
performed using DAVID58. Data analysis was implemented in R statistical envir-
onment (http://www.r-project.org/).
Rapid amplification of cDNA ends and cloning. RACE was performed using
SMARTer RACE kit (Takara Bio, Cat#634913) according to the manufacturer’s
instructions using RNA from hMDDCs stimulated for 2 h with 200 ng/ml LPS.
Briefly, after cDNA generation, 3′ and 5′ ends were amplified using SeqAmp DNA
polymerase and gene-specific primers (for 3′ RACE: 5′-gattacgccaagcttGT-
CAAGCTCGGATTGCCTTAGACAGGTGCA-3′ and for 5′ RACE 5′gattacgc-
caagcttAGGGACAGCTGGTAAGTGTAGCATCAGG-3′). Products were gel-
purified, cloned into the pRACE vector and transformed into Stellar competent
cells (Cat#CLT636766). Plasmids were isolated from single clones and sequenced at
Sequegen (Worcester, MA). LUCAT1 was cloned from 5′ RACE cDNA using Q5
Polymerase (NEB, Cat#M0491) with a 5′-specifc primer with a XhoI recognition
site (5′-ataccgctcgagAATCAACACTCCACTCAGACAATGCC-3′) and two dif-
ferent 3′-specifc primer with EcoRI recognition sites (Primer for the short isoform:
5′aggaattcTGAGACAGAGTCTCACTCTGTTGCC-3′; and primer for the long
isoform: 5′aggaattcGTATCTGCCTTTTCAGGCAGTGAAATC-3′). The amplicons
were cloned into PMSCV-PIG vector (addgene, #21654) using XhoI (NEB,
Cat#R0146S) and EcoRI (NEB, Cat#R0101S), transformed into Stbl3 competent
cells and sequenced at Genewiz (Cambridge, MA).
RNA isolation and RT-qPCR. Total RNA was isolated using Aurum Total RNA
mini kit (Bio-Rad Laboratories, Cat#7326820). RNA concentration was determined
using a spectrophotometer (Nanodrop, Thermo Fisher) and RNA with an A260/
A280 ratio >2.0 was considered as pure. RNA was reverse transcribed using iScript
cDNA Synthesis Kit (Bio-Rad Laboratories, Cat#1708891) and quantitative PCR
was performed using iTaq Universal SYBR green supermix (Bio-Rad Laboratories,
Cat#1725125) according to manufacturer’s instructions. Fold change in mRNA
expression was calculated using the comparative cycle method (2^-dCT) normal-
ized to the housekeeping gene GAPDH or HPRT. LUCAT1 copy numbers were
calculated using standard curves of LUCAT1 RT-qPCR products. Primers are listed
in Supplementary Table 1.
Loss of function studies. For RNA interference studies, short hairpin RNAs
(shRNA) targeting Exon 1 of LUCAT1 and non-targeting control shRNA were
cloned into the pLKO vector (addgene #8453). 4 µg of pLKO were transfected into
HEK293T cells together with packaging vectors 1 µg pxMD2.G (Addgene, #12259)
and 3 µg psPAX2 (Addgene, #12260) in 10 cm dishes using GeneJuice (Millipore,
#70967-6). After, 48 and 72 h the supernatant was collected and lentivirus was
concentrated using LentiX Concentrator (CloneTech, Cat#PT4421-2) according to
the manufacturer’s instructions. 100 µl of concentrated virus was added to 2 × 106
THP-1 cells for 48 h in presence of 8 µg/ml polybrene, followed by 2 µg/ml pur-
omycin (Corning, 61-385-RA) selection for 4–5 days. List of sequences in Sup-
plementary Table 2.
Gain of function studies. To create LUCAT1 overexpressing cells, Vp64 expressing
THP-1 cells were used (Dr. Patrick McDonel and Dr. Manuel Garber laboratory).
sgRNA were designed within −200 bp to 0 bp relative to the TSS of LUCAT1 and
cloned in 6 µg lentiguide puro vector (addgene, #52963) and transfected into
HEK293T cells with packing vectors- vectors 2 µg pxMD2.G (Addgene, #12259)
and 4 µg psPAX2 (Addgene, #12260) using GeneJuice(Millipore, #70967-6). After
48 h of culture, the culture media was isolated and concentrated for lentivirus using
LentiX concentrator (Clonetech, Cat#PT4421-2). 100 µl of concentrated virus was
added to 2 × 106 THP-1 cells for 48 h in presence of 8 µg/ml polybrene, followed by
2 µg/ml puromycin (Corning, 61-385-RA) selection. List of sequences in Supple-
mentary Table 3.
NanoString analysis. Cell stimulation and RNA isolation was performed as
described above. The nCounter analysis system was used for multiplex mRNA
measurements using a custom gene expression code-set against 250 proin-
flammatory genes. Total RNA (100 ng) was hybridized overnight with the gene
expression code-set and analyzed on an nCounter Digital Analyzer (Nanostring
Technologies). RNA hybridization, data acquisition, and analysis was performed as
per manufacturer’s specifications. RNA counts were processed to account for
hybridization efficiency, and mRNA expressions across experimental groups were
normalized to the geometric mean of six housekeeping genes.
Chromatin immunoprecipitation. After stimulations, the cells were fixed with 1%
formaldehyde, lysed, and sheared. The DNA was quantified, and 5 mg of total
chromatin was immunoprecipitated with specific antibodies and Dynabeads Pro-
tein G (Novex/Life Technologies #10009D). The DNA was then reverse cross-
linked, purified, and quantitated by quantitative PCR (qPCR) amplification with
primers designed at the promoter sites of the IFNB (F-5′-TCGTTTGCTTTCCT
TTGCTT-3′, R-5′-CCCACTTTCACTTCTCCCTTT-3′) and RSAD2 (F-5′-CCT
GGCATACAGGACACCTT-3′, R-5′ AAGAGTTCTGTCCGCTTCCA- 3′) genes
for RNA Polymerase II and H3K4me3 ChIP. For STAT1 ChIP, primers targeting
the STAT1-binding sites for CXCL10 (F-5′-AAAGGAACAGTCTGCCCTGA-3′,
R-5′-CACTGATGTCCTCCTGCTCA-3′), RSAD2 (F-5′- TTGGCCCTGTTTCA
ACTTTC-3′, R-5′-TCTGAGCAACCTGTCATTGG-3′), IFI16 (F-5′- ATTTCT-
CATCCCCCATTTCC-3′, R-5′-GAGACTCCTCCCACCAGTGT-3′), and MX2 (F-
5′ AGTTTGGGGACCACTCTGTG-3′, R-5′- CTGCTCCGTCATCAACAAAC-3′)
have been used. Antibodies used were against RNA Polymerase II (RNA Pol-II;
Active Motif #39097), Histone H3 trimethylated at Lysine 4 (H3K4me3; Abcam #
ab8580), STAT1 (Cell Signaling Technology, #9172), or control IgG isotype
(Abcam # ab37415 or Cell Signaling Technology #5415) as per manufacturer’s
recommended instructions. Data was calculated as the percentage fraction of total
input DNA and using IgG isotype as control.
Nanoblades. Nanoblades were produced as described by Mangeot, P. E et al.32.
HEK293T cells were plated at 70–80% confluency in a 10 cm dish in 10 ml of
Glutamax DMEM with 10% FBS and 1% pen/strep. 0.3 µg VSV-G, 0.7 µg BRL,
2.7 µg 5349, 1.7 µg BicCas9, 2.2 µg Blade for LUCAT1 sgRNA1, and 2.2 µg Blade
for LUCAT1 sgRNA2 were transfected in HEK293T cells using JetPrime (Polyplus
Transfection) according to the manufacturer’s instructions. VLP Nanoblade-
containing supernatant was collected 40 h post transfection, centrifuged at 500 g for
5 min, and filtered using a .45 µm syringe filter to remove cells and debris.
Nanoblades were pelleted by ultracentrifugation at 35,000 rpm on a SW41 rotor for
1.5 h and the pellet was resuspended in 100 µl of PBS. For LUCAT1 deletion,
primary hDCs were plated in 12 well plates with 1.5 million cells per condition in
400 µl of hDC conditioned medium as described above. 40 µl of resuspended
Nanoblades were added per well and incubated at 37 °C for 4–5 h followed by
careful addition of 600 µl of fresh medium. The cells were incubated with Nano-
blades for 48 h followed by stimulation and RNA/Protein analysis as described
above. List of sequences are given in Supplementary Table 3.
FISH and confocal microscopy. Fluorescence In-Situ Hybridization (FISH) was
carried out using ViewRNA ISH Cell Assay (Thermo Fisher) according to the
manufacturer’s protocol. Primary human DC cells were incubated on coverslips in
culture dishes with or without LPS stimulations. The cells were probed for LUCAT1
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(Alexa647) and GAPDH (Alexa488) mRNA. The cells were fixed and visualized
using confocal microscopy (Leica 8000) at 40× magnification for abundance and
localization. Data was quantified as the average number of puncta observed in
the cells.
Pulse chase. Pulse chase was performed as described in Garibaldi et al.31. 1.5 million
primary human DCs were plated in 6 well plate and stimulated with LPS simul-
taneously with addition of 500 µM 4SU in the media for 30 min, 1 h, 2 h, and 4 h.
The reaction was quenched by rapid addition of trizol at the end of each time point
followed by RNA extraction according to manufacturer’s protocol (Thermofisher,
TRIzol #15596026). 4SU RNA was incubated with 2 µl Biotin-HDPD (1 mg/ml) per
1 µg RNA and 1 µl Biotinylation buffer per 1 µg RNA at room temperature in dark
for 1.5 h. Post incubation, RNA was extracted using Phenol/chloroform extraction
and resuspended at 1 µg /µl concentration. Biotinylated samples were heated at
65 °C for 10 min and immediately placed on ice for 5 min. 100 µg of RNA was
added to 100 µl of streptavidin beads and incubated at room temperature for
15 min. µMACS columns were used for recovery of streptavidin-biotin labeled
RNA. µMACS columns were placed on magnetic stand and equilibrated using wash
buffer before putting labeled RNA. After three subsequent washes, RNA was eluted
using 100 µl of 100 mM DTT solution twice followed by EtOH precipitation. The
resulting RNA was then analyzed for gene expression using RT-qPCR.
RNA fractionation. THP-1 cells were fractionated into cytosolic and nuclear
compartments using detergent lysis method (Tsai et al., 2010). RNA was purified
from individual fractions using TRIzol (Thermofisher, TRIzol #15596026) and
reverse transcribed with oligo-dT primers using the cDNA synthesis kit (Agilent),
and subjected to qPCR analysis. Expressions of target genes in individual fractions
were normalized to their expression level in the input RNA, which was set as 100%.
ChIRP-MS. Cell lysis and sonication: ChIRP-MS was performed according to the
protocol from Chu et al. 50–60 million primary human DCs were plated in 15 cm
dishes in 15 ml primary human DC media and stimulated 200 ng/µl with LPS for
2 h. Post stimulation, cells were washed and collected in 50 ml conical tubes fol-
lowed by chemical crosslinking using 3% formaldehyde for 30 min at room tem-
perature. The cells were quenched using 0.5 M Glycine for 15 min at room
temperature. Cells were then pelleted by spinning at 2000 RCF for 3 min at room
temperature. Cell pellet was then resuspended in lysis buffer and sonicated using
water bath bioruptor in a 4 °C water bath at highest setting with 30 seconds ON,
45 seconds OFF pulse intervals. The lysates were then centrifuged at 16,100 RCF
for 10 min at 4 C and flash frozen in liquid nitrogen. Sonicated cell lysates in the
above step were thawed at room temperature and 10% of lysates were removed and
reserved as Input Controls. 2 ml of Hybridization buffer was added to each sample
along with 1 µl of 100 µM Control and LUCAT1 probes (List of ChIRP probes in
Supplementary Table 4). The probes-lysate mix was then incubated at 37 °C for 4 h
followed by addition of washed C1-magnetic beads (100 µl C1 beads to 100 pmol of
probes) to the hybridization mix and incubated for 30 min. Subsequently, the beads
were magnetically separated and washed for five times total and diluted in 1 ml of
wash buffer. 100 µl of resuspended beads were used for RNA extraction and 900 µl
for protein. 100 µl of beads were magnetically separated and resuspended in PK
buffer followed by heated shaking at 50 °C for 45 min. RNA was extracted using
TRizol as per manufacturer’s protocol. Primary human DC samples from two
independent donors stimulated with LPS and pulled down using control and
LUCAT1 probes were prepped for Mass Spectrometry. Samples were boiled Boil in
SDS-PAGE loading buffer in 35 µl volume and the entire reaction was loaded
onto a pre-cast SDS-PAGE gel (Invitrogen or biorad minigel). The samples were
ran till the dye front reached ~1.5 cm into the gel, stained and de-stained with
Coomassie. Excision of band and Mass spectrometry was performed at the Uni-
versity of Massachusetts MS core facility (https://www.umassmed.edu/MSF/). 0.2
pmol of yeast ADH digest was spiked into each of the samples and were run in
technical.
Generation of THP-1 LUCAT1-KO cell line. THP-1 KO cell lines were generated
using lentiviral transfer gRNAs into Cas9-expressing THP-1 cells. For lentiviral
production, 5×106 293 T Lenti-X cells (Takara) were plated into 10 cm cell culture
dishes and cultured o/n at 37 °C. At the next day, 5.1 µg lentiguide-puro or cherry
plasmid (addgene, #52963 and #99154, respectively), 4.3 µg psPAX2 (Addgene,
#12260), and 1.3 µg pMD2.G (Addgene, #12259) were transfected using JetPrime
transfection reagent (Polyplus transfection) according to the manufacturer’s
instructions. Transfection medium was changed after 4 h to 10 ml normal growth
medium. Supernatant was collected 24, 48, and 72 h after transfection, centrifuged
at 300×g for 10 min, filtered (.45 µm) and concentrated using Lenti-X concentrator
(CloneTech, Cat#PT4421-2). 0.5×106 THP-1 cells were transduced using 5 µg/ml
polybrene (Thermofisher #TR-1003-G) and 50 µl of concentrated lentivirus. To
excise exon 1 of LUCAT1, a combination of two gRNAs (5′-agattgccacagacaccca-3′
and 5′-aattggttcagcatctacca-3′) was used. 24 h post induction, 40 µg/ml puromycin
(Thermo Fisher) was added to cells and antibiotic selection was performed for
1 week. Limiting dilution was used to generate clonal cell lines. Excision of
LUCAT1 was checked using standard PCR with genomic DNA targeting LUCAT1
exon 1 (check primer, fwd: 5′-ctcccataaccctttgaagcct-3′; rev: 5′-gagccaagatca-
caccactgta-3′).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
RNA sequencing data are deposited in GEO under the primary accession code
GSE145451. Source data are provided with this paper.
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